Long-Term Outcomes of Cervical Cancer Patients Treated With Definitive Chemoradiation Following a Complete Metabolic Response.

AIMS: A complete metabolic response (CMR) on early post-treatment 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a positive prognostic factor for cervical cancer patients treated with definitive chemoradiation, but long-term outcomes of this group of patients are unknown. Patterns of failure and risk subgroups are identified. MATERIALS AND METHODS: Patients who received curative-intent chemoradiation from 1998 to 2018 for International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IVA cervical cancer and had a CMR on post-treatment FDG-PET within 5 months of treatment completion were included. Cox proportional hazards models determined factors associated with locoregional and distant failure. Kaplan-Meier estimates of freedom from any recurrence (FFR) of patient subgroups were compared with Log-rank tests. RESULTS: There were 402 patients with a CMR after chemoradiation on FDG-PET. Initial T stage was T1 (38%)/T2 (40%)/T3 (20%)/T4 (2%); initial FDG-avid nodal status was no nodes (50%)/pelvic lymph nodes (40%)/pelvic and para-aortic lymph nodes (10%). After a median follow-up of 6 years, 109 (27%) recurred. The pattern of recurrence was locoregional (27%), distant (61%) or both (12%). No factors were associated with locoregional failure. Distant recurrence was more likely in patients with T3-4 lesions (hazard ratio = 2.4, 95% confidence interval 1.5-3.8) and involvement of pelvic (hazard ratio = 1.6, 95% confidence interval 1.0-2.7) or para-aortic lymph nodes (hazard ratio = 2.7, 95% confidence interval 1.4-5.0) at diagnosis. The 5-year FFR rates for T1-2 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis were 85, 76 and 62%, respectively (P = 0.04, none versus para-aortic nodes). The 5-year FFR for T3-4 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis were 68, 56 and 25%, respectively (P = 0.09, none versus para-aortic nodes). CONCLUSIONS: T3-4 tumours and para-aortic nodal involvement at diagnosis are poor prognostic factors, even after a CMR following chemoradiation.

Nuclear imaging and cervical cancer.

The staging of patients with cervical cancer is in accordance with the International Federation of Gynecology and Obstetrics (FIGO) clinical staging system. The traditional and current radiographic imaging studies allowed by FIGO to influence the clinical stage of the disease are the chest X-ray, the intravenous urogram and plain X-rays of the skeleton. The development and use of complimentary imaging studies may guide and direct therapy, but it does not change the clinical stage of the disease. Other X-ray studies that have been used are the barium enema and the lymphangiogram. Both computerized tomography (CT) and magnetic resonance imaging (MRI) have become commonplace in the evaluation of these patients. Most recently, position emission tomography (PET) with CT (PET/CT) is the preferred whole-body imaging study for patients with invasive cervical cancer. Single photon emission computed tomography (SPECT) combined with CT, the SPECT/CT, is also now being utilized in patients with cervical cancer. These new imaging modalities permit increased accuracy in the diagnosis and staging of cervical cancer, improve the selection and guidance of therapy, reduce uncertainties in the monitoring of response to therapy, and provide a means for objective long-term surveillance.

FDG-PET/CT: new horizons in anal cancer.

Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries. Its incidence seems to be increasing because of exposure to human immunodeficiency virus (HIV) and human papillomavirus (HPV). Traditional pretreatment evaluations include physical examination and CT imaging of the pelvis. Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer. At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases. FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor. Posttherapy FDG-PET/CT to determine response to therapy is highly predictive of long-term clinical outcomes. This imaging modality can also be used to evaluate sites of recurrent disease. FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.

MicroRT-small animal conformal irradiator.

A novel small animal conformal radiation therapy system has been designed and prototyped: MicroRT. The microRT system integrates multimodality imaging, radiation treatment planning, and conformal radiation therapy that utilizes a clinical 192Ir isotope high dose rate source as the radiation source (teletherapy). A multiparameter dose calculation algorithm based on Monte Carlo dose distribution simulations is used to efficiently and accurately calculate doses for treatment planning purposes. A series of precisely machined tungsten collimators mounted onto a cylindrical collimator assembly is used to provide the radiation beam portals. The current design allows a source-to-target distance range of 1-8 cm at four beam angles: 0 degrees (beam oriented down), 90 degrees, 180 degrees, and 270 degrees. The animal is anesthetized and placed in an immobilization device with built-in fiducial markers and scanned using a computed tomography, magnetic resonance, or positron emission tomography scanner prior to irradiation. Treatment plans using up to four beam orientations are created utilizing a custom treatment planning system-microRTP. A three-axis computer-controlled stage that supports and accurately positions the animals is programmed to place the animal relative to the radiation beams according to the microRTP plan. The microRT system positioning accuracy was found to be submillimeter. The radiation source is guided through one of four catheter channels and placed in line with the tungsten collimators to deliver the conformal radiation treatment. The microRT hardware specifications, the accuracy of the treatment planning and positioning systems, and some typical procedures for radiobiological experiments that can be performed with the microRT device are presented.

Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.

PURPOSE: The aim of this study was to compare the results of computed tomography (CT) and positron emission tomography (PET) with [18F]-fluoro-2-deoxy-D-glucose (FDG) for lymph node staging in patients with carcinoma of the cervix and to evaluate the relationship of the imaging findings to prognosis. PATIENTS AND METHODS: We retrospectively compared the results of CT lymph node staging and whole-body FDG-PET in 101 consecutive patients with carcinoma of the cervix. Patients were treated with standard irradiation and chemotherapy (as clinically indicated) and observed at 3-month intervals for a median of 15.4 months (range, 2.5 to 30 months). Progression-free survival was evaluated by the Kaplan-Meier method. RESULTS: CT demonstrated abnormally enlarged pelvic lymph nodes in 20 (20%) and para-aortic lymph nodes in seven (7%) of the 101 patients. PET demonstrated abnormal FDG uptake in pelvic lymph nodes in 67 (67%), in para-aortic lymph nodes in 21 (21%), and in supraclavicular lymph node in eight (8%). The 2-year progression-free survival, based solely on para-aortic lymph node status, was 64% in CT-negative and PET-negative patients, 18% in CT-negative and PET-positive patients, and 14% in CT-positive and PET-positive patients (P <.0001). A multivariate analysis demonstrated that the most significant prognostic factor for progression-free survival was the presence of positive para-aortic lymph nodes as detected by PET imaging (P =.025). CONCLUSION: This study demonstrates that FDG-PET detects abnormal lymph node regions more often than does CT and that the findings on PET are a better predictor of survival than those of CT in patients with carcinoma of the cervix.

Primary radiotherapy for stage IB or IIA cervical cancer.

Patients with carcinoma of the cervix (stages IB-IIA) have a tumor that is confined to the cervix and upper vagina. These patients, however, may have a tumor that ranges in diameter from less than 1 cm to as large as 10 cm. The survival for all patients with stage IB disease is 86%; for those with stage IIA disease, it is 72%. Reports of radiotherapy alone for small stage IB or IIA cervical cancer indicate a cure rate of greater than 90% and a severe complication rate of less than 5%. Bulky cervical cancers of stages IB-IIA treated with high doses of radiation have survival and complication rates that are dependent on tumor size, and no survival benefit has been demonstrated with the addition of a hysterectomy. Elective para-aortic irradiation has been demonstrated to be of benefit in this patient population. The quality of life for patients treated with radiotherapy alone depends on many factors.

Carcinoma of the urethra in women.

PURPOSE: This analysis was performed to evaluate the influence of clinical and treatment factors on local tumor control, survival, and complications for women with urethral carcinoma. METHODS AND MATERIALS: The records of 44 women with carcinoma of the urethra were reviewed. Their age ranged from 37 to 89 years (mean, 67 years). Mean follow-up time was 8.25 years. The stages of disease were T1 in eight, T2 in five, T3 in 22, and T4 in nine. Treatment was with surgery in 7, radiotherapy in 25, and combined surgery and radiotherapy in 12. RESULTS: The 5-year overall survival was 42% and the 5-year cause-specific survival was 40%. At the time of last follow-up, 11 women were alive and 33 were dead. Recurrence of tumor occurred in 27 women and was the cause of death for 23. Recurrence was local in 8, local and distant in 15, and distant in 4. Severe complications occurred in nine women (20%). The severe complication rate was 29% (2 of 7) for women treated with surgery, 24% (6 of 25) for women treated with radiotherapy, and 8% (1 of 12) for women treated with surgery and radiotherapy. A multivariate analysis was performed to evaluate the interaction of tumor size, histology, and location, and lymph node status. This analysis indicated that tumor size and histology were independent prognostic factors for survival and local tumor control. Adenocarcinoma occurred in 13 women, and none of them were alive at 5 years. Only 1 of 10 women with tumors greater than 4 cm was alive at 5 years. CONCLUSIONS: The most significant clinical factors affecting prognosis were tumor size and histology. Tumor location was not an independent prognostic variable. None of the women with adenocarcinoma, and only one woman with a tumor greater than 4 cm was alive at 5 years, irrespective of modality of treatment. Aggressive treatment resulted in a high complication rate.

Gapping fields on sloping surfaces.

The accurate positioning of treatment fields has always been difficult, and becomes even more important when two fields are adjacent and a gap must be calculated. The standard formula (based on similar triangles) assumes a flat surface. In Hodgkin's patients the gapping between the mantle and para-aortic fields involve sloping surfaces and the patient thickness can vary as much as 5 or 6 cm between central axis and the lower edge of the mantle field. Due to the divergence of a large mantle field, using the standard formula and gapping on the skin surface can lead to an overlap of 7 to 9 mm and a region which can receive 140% of the midplane dose. A modification of the existing formula which takes into account sloping surfaces has been formulated for both source-skin-distance and isocentric treatments. In addition, problems in positioning related to mantle fields when treating the patient prone and supine have been investigated.

Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ.

The objective of this study was to define the role of radiotherapy alone for medically inoperable patients with Carcinoma in Situ (CIS) and Stage IA carcinoma of the uterine cervix. At the Mallinckrodt Institute of Radiology, Radiation Oncology Center from January 1959 through December 1986 21 patients with CIS and 34 with Stage IA were treated. All patients had histologically proven disease. The average age was 56 years for CIS and 51 years for Stage IA patients. Therapy for patients with CIS consisted of a single intracavitary insertion with a uterine tandem and colpostats. The average radiation doses were 4612 cGy to point A, 9541 cGy to the surface of the cervix, and 5123 milligram-hours (mgh). Radiotherapy for Stage IA tumors was delivered with intracavitary irradiation alone in 13 (average doses were 5571 cGy to point A, 10,430 cGy vaginal surface dose, and 6488 mgh). The other 21 patients were treated with external beam and intracavitary irradiation. The average whole pelvis dose was 1443 cGy with an additional 2354 cGy boost to the parametria with a midline stepwedge shield. The average intracavitary doses were 5200 cGy to point A, 10234 cGy to the vaginal surface, and 6293 mgh. None of the patients with CIS developed recurrent disease and none had severe sequelae of therapy. Only one patient with Stage IA developed recurrent disease in the pelvis. None developed metastatic disease. The severe complication rate was 5.9% (2/34) for Stage IA and only occurred in those receiving intracavitary irradiation and external beam irradiation. We conclude that irradiation consisting of intracavitary implants alone is excellent treatment for patients with medically inoperable Stage IA and CIS of the cervix.

Design of an afterloading vaginal applicator (MIRALVA).

A vaginal applicator was designed and constructed that incorporates two ovoid sources and a central tandem which can be utilized to treat the entire vagina (alone or in combination with the uterine cervix). The average surface dose rate around the 2 cm ovoids is 120 cGy/hr and in the 2.5 cm diameter vaginal cylinder about 100 cGy/hr with usual loading of 20 mg Ra eq 137-Cs sources in the ovoids and 10-15 mg Ra eq 137-Cs sources in the cylinder. The applicator has vaginal apex caps and additional cylinder sleeves that allow for increased dimensions. The tandem in the uterus can be utilized when clinically indicated using standard loadings, depending on the depth of the uterus (20-10-10 or 20-10 mg Ra eq). When the tandem and vaginal cylinder are utilized the strength of the sources in the ovoids should be 15 mg Ra eq. The vaginal cylinder or uterine tandem never carry an active source at the level of the ovoids. Thermoluminescent dosimetry measurements throughout the surface of the applicator showed close agreement with the computer dose calculations (within +/- 2%). The acronym MIRALVA describes the device (Mallinckrodt Institute of Radiology Afterloading Vaginal Applicator).

Radiation induced lumbosacral plexopathy in gynecologic tumors: clinical findings and dosimetric analysis.

PURPOSE: Radiation-induced lumbosacral plexopathy is a rare complication of pelvic irradiation. METHODS AND MATERIALS: We report four cases among 2,410 patients treated to the pelvis for carcinoma of the cervix and carcinoma of the endometrium. All patients received both external beam and intracavitary radiation. The total calculated dose to the lumbosacral plexus was on the order of 7300 cGy. RESULTS: All 4 cases presented developed lumbosacral plexopathy. CONCLUSIONS: Although a few permanent lumbosacral lesions have been reported for patients treated with conventionally fractionated external beam, this syndrome is more often seen in patients treated with intracavitary irradiation for cervical or endometrial carcinoma.

Improvements in brachytherapy quality assurance.

Quality assurance (QA) for a busy brachytherapy service is a demanding task which requires the involvement of the entire brachytherapy team. This communication describes the QA program for brachytherapy procedures and source identification and inventory which is currently practiced at the Radiation Oncology Center, Mallinckrodt Institute of Radiology.

Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas.

Prognostic factors and results of therapy were analyzed in a retrospective review of 70 patients with pituitary adenomas treated with radiotherapy alone from January 1954 through December 1982 at the Radiation Oncology Center, Mallinckrodt Institute of Radiology. The 10-year overall and disease-free survival was 77.8 and 76.0%. The expected survival for an age-, sex-, and race-matched population was not significantly greater at 87.2%. The 10-year disease-free survival for the distinct tumor types was 100% for Cushing's disease, 82.3% for patients with amenorrhea/galactorrhea, 79.6% for non-functioning adenomas, 69.0% for acromegaly, and 66.7% for Nelson's syndrome. Prognostic variables analyzed were age, race, sex, tumor type, tumor extent, visual field defects at diagnosis, and volume irradiated. Only the presence of visual field defects at diagnosis conferred a poor prognosis (p less than 0.001). There was a tendency toward superior tumor control with radiation doses greater than 4500 cGy (p = 0.15). The median time to progression of disease was 4.2 years, with the last failure occurring at 12 years following the completion of radiotherapy. Severe complications were apparent in 5 patients (7.1%), including one death from central nervous system radionecrosis.

Distant metastases after irradiation alone in carcinoma of the uterine cervix.

This is a retrospective analysis of 1211 patients with invasive carcinoma of the uterine cervix treated with irradiation alone from 1959 through 1986, of whom 322 developed distant metastases during the course of the disease. The 10-year actuarial incidence of distant metastases was 3% in Stage IA (34 patients), 16% in Stage IB (384 patients), 31% in Stage IIA (128 patients), 26% in Stage IIB (353 patients), 39% in Stage III (292 patients), and 75% in Stage IVA (20 patients). A multivariate analysis of factors influencing the incidence of distant metastases showed clinical stage, endometrial extension noted by dilatation and curettage (D&C) prior to therapy, and pelvic tumor control within each stage to be significant indicators of distant dissemination; histology, volume of disease, and age of patient were not significant. The frequency of metastases in all stages except IVA was greater when endometrial tumor extension was detected by D & C before to definitive irradiation (Stage IB, 28%; Stage IIA, 48%; Stage IIB, 42%; Stage III, 72%; and Stage IVA, 75%). In contrast, with normal D & C findings, the incidence of distant metastases was 15% in Stage IB, 29% in Stage IIA, 25% in Stage IIB, 45% in Stage III, and 84% in Stage IVA. The incidence of metastases in patients with pelvic tumor control was 11% in Stage IB, 22% in Stage IIA, 21% in Stage IIB, 34% in Stage III, and 50% in Stage IVA; in contrast, the corresponding incidence in patients failing in the pelvis was 76% in Stage IB, 88% in Stage IIA, 62% in Stage IIB, 87% in Stage III, and 74% in Stage IVA. The frequency of metastases per histology was comparable in squamous cell carcinoma and other histologic types. The incidence of metastases to other organs was 56%: Most frequent sites were lung, abdominal cavity, liver, and gastrointestinal tract. The incidence of clinically apparent lymph node involvement was 22%, predominantly to paraaortic, supraclavicular, and inguinal nodes. Bone metastases occurred in 16% of the patients, most commonly to the lumbar and thoracic spine. Despite aggressive local therapy with excellent local control, the incidence of distant metastases in patients with invasive carcinoma of the uterine cervix is high. The management of these patients and their response to salvage therapy are discussed. The need for effective adjuvant systemic therapy in the management of patients with invasive carcinoma of the cervix is also discussed.

Source configuration and dose rates for the Selectron afterloading equipment for gynecologic applicators.

This paper describes source train configurations of the Selectron LDR-6 that can be used to duplicate commonly used manually afterloadable source configurations for gynecological intracavitary brachytherapy. We demonstrate that the recommended source configuration using 2.5 mm 137Cs spheres is dosimetrically equivalent to its manually afterloaded counterparts using 3M 137Cs sources (20 mm overall length, 14 mm active length). Isodose distributions are in agreement to within 5% for the Fletcher-Suit-Delclos family of tandems, colpostats, and vaginal cylinders. Our data also demonstrate that the isotropic point source model used by most computerized treatment planning systems is a good approximation to source trains of filtered, spherical sources interspersed with solid steel spacers. We conclude that the use of 2.5 mm 137Cs sources in the Selectron remote afterloading system can accurately reproduce the isodose distribution achieved with linear 137Cs manually afterloaded sources.

Anatomic variation of gynecologic brachytherapy prescription points.

PURPOSE: The purpose of this report is to evaluate the geometric movement (relative to the bony pelvis) of fixed brachytherapy reference points during the time interval of the first and second gynecologic intracavitary implant. METHODS AND MATERIALS: The radiation therapy records of 40 consecutive patients with all stages of carcinoma of the cervix treated at the Radiation Oncology Center, Mallinckrodt Institute of Radiology, from January 1991 through December 1991 were reviewed. All patients received external beam irradiation and two intracavitary implants with Fletcher-Suit tandem and ovoids. Prescription points, per ICRU #38, were used: point A, B, and P, bladder, and rectum. Comparison of the location of points for the first and second implants (2 weeks time interval) was performed using the bony pelvis as reference anatomy and calculating the 3-dimensional spherical coordinates from a common origin for both implants. RESULTS: Analysis of the movement of the second implant relative to the first revealed that the x, y, and z coordinates for the various points shifted from 0 to 6 mm in a single plain. Vector analysis showed that the magnitude and direction of the average shift was on the order of 1.0 to 1.5 cm with displacement posteriorly and inferiorly. The effect of this movement on dose rates to the various points can result in dose rate differences up to 35%. A regression analysis was performed to identify factors affecting this movement. The time interval from the first to the second implant was the factor which correlated best with the movement. CONCLUSION: There is movement of the absolute position of ICRU #38 reference points between the first and second intracavitary implants. This movement results in significant differences in absolute dose rates to these reference points in the two implants. The clinical significance of this movement relative to dose to the tumor is unknown.

Recurrent carcinoma of the cervix exclusively in the paraaortic nodes following radiation therapy.

PURPOSE: This is a retrospective analysis of 1211 patients with invasive carcinoma of the uterine cervix treated with irradiation alone at the Mallinckrodt Institute of Radiology from 1959 through 1986, of whom 20 developed their first recurrence exclusively in the paraaortic lymph nodes. METHODS AND MATERIALS: The incidence of clinically/radiographically detected paraaortic node recurrence by stage at original diagnosis was 1.8% in Stage IB (7/384 patients), 2.3% in Stage IIA (3/128 patients), 1.4% in Stage IIB (5/353 patients), 1.4% in Stage III (4/292 patients), and 5% in Stage IVA (1/20 patients). Forty-five percent of para-aortic node recurrences were observed within the first 12 months after initial diagnosis and 75% within the first 2 years. Sciatic pain, leg edema, and hydronephrosis were identified in most patients. Patients were treated with external irradiation only to the paraaortic lymph nodes. RESULTS: All patients died within 2 years of paraaortic recurrence. Median survival for the entire group was 8.7 months. Median survival was 7.5 months for those failing within 24 months of the original diagnosis compared with 17.8 months for those failing after 24 months from original diagnosis (p = 0.09). Patients who received > 4500 cGy had a median survival of 14.2 months compared with 7.1 months for those treated with < 4500 cGy to the paraaortic recurrence (p = 0.004). Forty-five percent of patients developed mild to moderate nausea during paraaortic irradiation; however, no severe complications from the radiation therapy were noted. CONCLUSION: Sciatic pain, leg edema, and hydronephrosis commonly occur in patients with paraaortic node recurrence. The presence of these symptoms in a patient with a history of carcinoma of the cervix should initiate an aggressive evaluation.

Acute phase response during radiotherapy.

PURPOSE: The acute phase response is characterized by changes in the plasma concentrations of a number of liver-synthesized proteins, one of which is C-reactive protein (CRP). The existence of these changes in the plasma profile underlies the change in erythrocyte sedimentation rate (ESR). Acute phase response itself is an illness and may result from immunologic reactions and inflammatory processes. This study is designed to determine whether the CRP level and ESR increase during radiotherapy and whether their rise correlates with acute and late radiation morbidity. METHODS AND MATERIALS: Between April 1997 and October 1998, 51 patients with the diagnosis of endometrium and cervical cancer were treated with surgery and postoperative radiotherapy. Median age at the time of radiotherapy was 52 (range, 26-73) years. Thirty patients received pelvic radiotherapy, and 21 patients were treated by pelvic-paraaortic irradiation. A total dose of 50.4 Gy to the pelvis and 45 Gy to the paraaortic field were delivered in conventional fraction. Erythrocyte sedimentation rates and CRP levels were studied before, during, and at the end of radiotherapy. RESULTS: The mean ESR measurements before and after radiotherapy were 40 (8-100) and 52 (10-120), and mean CRP levels were 1.4 (0.12-9.8) and 2.7 (0.12-32.2), respectively. The statistical analysis yielded significant rise in ESR and CRP levels at the end of radiotherapy (p < 0.001). The increase was more prominent in patients who were irradiated through pelvic-paraaortic field than in patients with pelvic radiation (p = 0.005 and 0.028 respectively). CONCLUSION: Acute phase response was present during radiotherapy. Radiotherapy should be considered as a cause of increase in CRP level and ESR especially in clinical conditions where acute phase response is important.

Femoral neck fracture following groin irradiation.

PURPOSE: The incidence and risk factors are evaluated for femoral neck fracture following groin irradiation for gynecologic malignancies. METHODS AND MATERIALS: The radiation therapy records of 1313 patients with advanced and recurrent cancer of the vagina, vulva, cervix, and endometrium, treated at the Mallinckrodt Institute of Radiology from 1954 to 1992, were reviewed. Median follow-up was 12.7 years. From this group, 207 patients were identified who received irradiation to the pelvis and groins with anterposterior-posterior anterior (AP-PA), 18 MV photons. Data were reviewed regarding irradiation dose to the femoral neck and other presumed risk factors including age, primary site, stage, groin node status, menopausal status, estrogen use, cigarette use, alcohol consumption, and osteoporosis. RESULTS: The per-patient incidence of femoral neck fracture was 4.8% (10 out of 207). Four patients developed bilateral fractures. However, the cumulative actuarial incidence of fracture was 11% at 5 years and 15% at 10 years. Cox multivariate analysis of age, weight, and irradiation dose showed that only irradiation dose may be important to developing fracture. Step-wise logistic regression of presumed prognostic factors revealed that only cigarette use and x-ray evidence of osteoporosis prior to irradiation treatment were predictive of fracture. CONCLUSION: Femoral head fracture is a common complication of groin irradiation for gynecologic malignancies. Fracture in our database appears to be related to irradiation dose, cigarette use, and x-ray evidence of osteoporosis. Special attention should be given in treatment planning (i.e., shielding of femoral head/neck and use of appropriate electron beam energies for a portion of treatment) to reduce the incidence of this complication.

Multivariate analysis of prognostic factors in pediatric and adult thalamic and brainstem tumors.

A multivariate analysis of prognostic variables was performed on a retrospective review of 136 patients with presumed or histologically proven primary lesions of the thalamus and brainstem treated by combined surgery and post-operative irradiation or by irradiation alone from January 1950 through December 1983. Overall survival for all patients at 5 and 10 years was 34.4 and 27.8%, respectively. Follow-up of 33 living patients ranged from 3 to 22 years. Prognostic variables analyzed by univariate analysis and found to be of significance (p less than 0.05) were race, duration of symptoms, extent of surgery (i.e. subtotal excision), and dose of irradiation. Further evaluation by Cox regression analysis revealed these same factors to be of prognostic significance (p less than 0.05). It is of importance to note that age and tumor site were not significant prognostic variables in the multivariate analysis but were significant by univariate analysis. The 5-year overall survival for patients with thalamic tumors was 59.5 and 20.9% for children and adults, respectively (p = 0.006). The 5-year overall survival for patients with pontine lesions was 46.6 and 16.0% for adults and children, respectively (p = 0.01). Only one patient was known to have expired due to a complication of therapy. Neurologic deficits and functional ability was normal or mild in 57.6% of the surviving patients.